Beth Faiman talks about the excitement of new medications but the challenge of getting to a standard of care that includes these new drugs.
There are so many things that we could do to improve the standard of care for all patients with hematologic malignancies, specifically multiple myeloma. We just discussed that there are four new drugs FDA approved in 2015. Some of the challenges with those new drugs are what to use when, how to take the drugs, and how these drugs should be best administered.
We've gotten so far with research in the last 20 years, specifically the last 10 years with myeloma. We still don't have the optimal front line regimen. That means when patients are newly diagnosed, we have so many drugs, it's a challenge to know what to use best. In order to improve the standard of care, we would like to continue to do more research.